Taylor Mandrill, Petrakis Ismene, Ralevski Elizabeth
a VISN I Mental Illness Research Education and Clinical Center (MIRECC), VA Connecticut Healthcare System and Yale University School of Medicine , Department of Psychiatry , West Haven , CT , USA.
Am J Drug Alcohol Abuse. 2017 Jul;43(4):391-401. doi: 10.1080/00952990.2016.1263641. Epub 2016 Dec 23.
Alcohol use disorder (AUD) is a serious psychiatric disorder with medical, psychiatric, and social consequences. In individuals with comorbid post-traumatic stress disorder (PTSD), treatment outcomes are notably worse in comparison with treatment outcomes associated with either disorder occurring alone. There is a growing literature evaluating treatments, both pharmacotherapy and psychotherapy focused, in individuals with co-occurring AUD and PTSD. The main objective of this review was to evaluate pharmacotherapy and psychotherapy studies that were specifically designed to evaluate the treatment of individuals with comorbid AUD and PTSD.
MEDLINE and PUBMED databases were searched with no specific time period. Studies focusing on SUD treatments were excluded. Because the number of random clinical trial (RCT) studies was small, all publications (including open label, single case, and secondary analyses) were included.
Sixteen studies met criteria and were organized based on whether they evaluated the efficacy of pharmacotherapy, psychotherapy, or both. Pharmacological interventions with either AUD or PTSD agents were mainly effective in reducing drinking outcomes; only one study using sertraline found that the active study medication was superior to placebo in reducing PTSD symptoms. Psychotherapies were not superior to a comparative treatment in reducing drinking outcomes. Only 1 study showed reduction in PTSD symptoms in a small sample of completers. The single RCT that evaluated the efficacy of naltrexone in combination with psychotherapies (prolonged exposure or supportive counseling) found that naltrexone in combination with prolonged exposure was better for drinking outcomes at follow-up.
Although these studies represent a good start in terms of research in treatment interventions of co-occurring AUD and PTSD, the studies are very limited, most lack adequate power, and the majority suffer from inadequate control groups. In particular, there is a strong need to develop and evaluate the combined medication and psychological-based treatment interventions for those with comorbid AUD and PTSD.
酒精使用障碍(AUD)是一种严重的精神疾病,会产生医学、精神和社会后果。在患有创伤后应激障碍(PTSD)合并症的个体中,与单独发生的任何一种疾病相比,治疗效果明显更差。越来越多的文献评估了同时患有AUD和PTSD的个体的治疗方法,包括药物治疗和心理治疗。本综述的主要目的是评估专门设计用于评估合并AUD和PTSD个体治疗的药物治疗和心理治疗研究。
对MEDLINE和PUBMED数据库进行检索,无特定时间段限制。排除专注于物质使用障碍治疗的研究。由于随机临床试验(RCT)研究数量较少,纳入了所有出版物(包括开放标签、单病例和二次分析)。
16项研究符合标准,并根据它们是否评估了药物治疗、心理治疗或两者的疗效进行组织。使用AUD或PTSD药物的药理学干预主要在减少饮酒结果方面有效;只有一项使用舍曲林的研究发现,活性研究药物在减轻PTSD症状方面优于安慰剂。心理治疗在减少饮酒结果方面并不优于对照治疗。只有1项研究在一小部分完成者样本中显示PTSD症状有所减轻。评估纳曲酮与心理治疗(延长暴露或支持性咨询)联合疗效的单一RCT发现,纳曲酮与延长暴露联合在随访时对饮酒结果更好。
尽管这些研究在AUD和PTSD共病治疗干预研究方面是一个良好的开端,但研究非常有限,大多数缺乏足够的效力,并且大多数存在对照组不足的问题。特别是,迫切需要为合并AUD和PTSD的个体开发和评估联合药物和基于心理的治疗干预措施。